CapitolRadar tracks every publicly disclosed ABBV trade by US congress members and corporate insiders: 77 disclosed trades (49 buys, 28 sells) by 9 tracked traders, from 2019-12-11 to 2026-09-14. Updated daily from official filings.
Want a ping when Congress buys ABBV? Free email alerts on notable disclosed trades — plus a $100,000 fantasy portfolio to play along against three AI traders. Join free
AbbVie Inc. (ABBV) — Healthcare · Drug Manufacturers - General, market cap about $500.8B.
CapitolRadar analysis
69 disclosed ABBV trades, with buys outnumbering sells
44 buys versus 25 sells make up the 69 tracked AbbVie disclosures filed by seven distinct traders from December 11, 2019 through May 5, 2026. The activity therefore leans toward purchases by transaction count, with buys representing 44 of the 69 records. This is a count of disclosed trades, not a measure of net dollars invested or a conclusion about trader sentiment.
The most recent listed quarters are small samples. In 2026 Q2, there were two trades—one buy and one sell—while 2026 Q1 had one trade and no buys. Earlier listed periods were more purchase-heavy: 2025 Q3 had two buys in two trades, 2025 Q2 had four buys among five trades, and 2025 Q1 had one buy. The listed 2024 quarters contained seven trades, six of which were buys. Quarter-to-quarter comparisons should be treated cautiously because several periods contain only one or two disclosures.
23 Ro Khanna buys account for over half of purchases
23 of the 44 buys were attributed to Ro Khanna, whose latest listed purchase was May 1, 2026. Josh Gottheimer followed with nine buys, most recently on May 22, 2025, and Marjorie Taylor Greene had five, most recently on August 4, 2025. Tommy Tuberville recorded three buys, while Lois Frankel and Diana Harshbarger recorded two each. Together, these six named buyers account for all 44 tracked purchases, although the overall dataset includes seven distinct traders.
Cross-holdings show limited overlap
Two ABBV buyers each also bought GOOGL, FCX, PANW and ADI. One buyer each also purchased MSCI and ORLY. These overlaps involve very small groups and do not establish a common strategy or motive.
Congressional transaction reports can be filed up to 45 days after a trade, so disclosure dates may lag the underlying activity. Reported transaction values are provided in ranges, making any dollar amounts estimates rather than exact figures. Those timing and valuation limits, along with the small quarterly samples, constrain interpretation.
Analysis written from the tracked record on 2026-09-04; it is refreshed whenever the underlying numbers change.
Activity by quarter
| Quarter | Disclosed trades | Buys | Sells |
|---|---|---|---|
| 2026 Q3 | 2 | 0 | 2 |
| 2026 Q2 | 2 | 1 | 1 |
| 2026 Q1 | 1 | 0 | 1 |
| 2025 Q3 | 3 | 3 | 0 |
| 2025 Q2 | 6 | 5 | 1 |
| 2025 Q1 | 2 | 2 | 0 |
| 2024 Q4 | 2 | 2 | 0 |
| 2024 Q2 | 1 | 1 | 0 |
Who is buying ABBV?
| Trader | Disclosed buys | Last buy | Grade |
|---|---|---|---|
| Ro Khanna | 24 | 2026-05-01 | — |
| Josh Gottheimer | 9 | 2025-05-22 | — |
| Marjorie Taylor Greene | 5 | 2025-08-04 | — |
| Lois Frankel | 4 | 2023-09-06 | — |
| Tommy Tuberville | 3 | 2024-04-03 | — |
| Jared Moskowitz | 2 | 2025-04-07 | — |
| Diana Harshbarger | 2 | 2022-06-21 | — |
Disclosed trades in ABBV
| Date | Who | Type | Amount | 30d vs SPY |
|---|---|---|---|---|
| 2026-09-14 | Pete Sessions | sell | $15,001 - $50,000 | — |
| 2026-09-04 | Ro Khanna | sell | $15,001 - $50,000 | — |
| 2026-05-05 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2026-05-01 | Ro Khanna | buy | $15,001 - $50,000 | — |
| 2026-01-29 | Ro Khanna | sell | $15,001 - $50,000 | — |
| 2025-08-04 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-08-04 | Ro Khanna | buy | $1,000 - $15,000 | — |
| 2025-08-04 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2025-05-22 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2025-05-05 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-04-17 | Josh Gottheimer | sell | $1,001 - $15,000 | — |
| 2025-04-07 | Jared Moskowitz | buy | $1,001 - $15,000 | — |
| 2025-04-03 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2025-04-01 | Josh Gottheimer | buy | $1,001 - $15,000 | — |
| 2025-03-17 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2025-01-15 | Jared Moskowitz | buy | $1,001 - $15,000 | — |
| 2024-11-20 | Marjorie Taylor Greene | buy | $1,001 - $15,000 | — |
| 2024-10-14 | Ro Khanna | buy | $1,001 - $15,000 | — |
| 2024-04-03 | Tommy Tuberville | buy | $1,001 - $15,000 | — |
| 2024-02-13 | Ro Khanna | buy | $1,001 - $15,000 | — |
These buyers also bought
Other stocks the tracked buyers of ABBV disclosed buying in the last six months: MSFT (3) · HD (2) · GOOGL (2) · SNDK (2) · AMD (2) · RSG (2).
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCL…
Frequently asked questions
Which politicians bought ABBV most?
Ro Khanna leads with 24 disclosed buys, followed by Josh Gottheimer.
How current is this page?
It re-renders from the tracked record on every view and new filings are ingested daily — but STOCK Act disclosures can lag the trade by up to 45 days, so the most recent weeks are always incomplete.
Get alerts when trades like these are disclosed. Free account: fantasy portfolio + email alerts. Premium: a 6-hour head start on every signal.
CapitolRadar tracks publicly disclosed trades (STOCK Act filings and SEC Form 4). Disclosures can lag the trade by up to 45 days. Backtests measure past disclosed buys against the S&P 500 and do not predict future results. Everything on this page is impersonal information for your own research — not investment advice.